Skip to main content
. 2015 Sep 4;6(31):31018–31029. doi: 10.18632/oncotarget.5041

Figure 4. Gemcitabine-GCV combination treatment in EBVaGC cell-implanted mice.

Figure 4

A. Gemcitabine/GCV administration. Tumor volume in mice implanted with B. SNU-719 or C. MKN-74 cells and injected intraperitoneally with 10 mg/kg gemcitabine, 25 mg/kg GCV, or both according to the schedule shown in above. Body weight in D. SNU-719- or E. MKN-74-implanted mice injected intraperitoneally with 10 mg/kg gemcitabine, 25 mg/kg GCV, or both according to the schedule shown above. Tumor mass and body weight were measured before every gemcitabine injection. Each data point reflects observations from five mice. Both values were calculated as the percentage of the initial value for each mouse. Values represent means ± SEM.